Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
4-hydroxyphenylpyruvate dioxygenase-like protein (HPDL) is a mitochondrial iron-dependent enzyme, structurally related to 4-hydroxyphenylpyruvate dioxygenase but with distinctive, yet incompletely characterized, activity. HPDL localizes to the mitochondrial intermembrane space and is implicated in regulating mitochondrial respiration and cellular ATP production through glutamine metabolism. It plays an essential role in maintaining redox balance via a glutamine-dependent antioxidant pathway, and protects against oxidative stress. HPDL overexpression is associated with pancreatic cancer progression and poorer outcomes, while biallelic mutations in HPDL result in neurodegenerative conditions such as hereditary spastic paraplegia (SPG83). Though its exact substrate and enzymatic products remain undefined, HPDL's function is critical for cellular metabolism, redox homeostasis, and potentially for neuronal integrity and cell survival in disease.
Not established drug mechanisms, but molecular function involves mitochondrial bioenergetics regulation and redox balance, especially via glutamine metabolism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 4-hydroxyphenylpyruvate dioxygenase-like protein (HPDL).